| Private Placement / Financing Transactions
Abcuro: The company raised $200 million of Series C venture funding in a deal led by New Enterprise Associates on February 12, 2025, putting the company’s pre-money valuation at $500 million. Sanofi Ventures, Bain Capital Life Sciences, Eurofarma Ventures, Foresite Capital, Soleus Capital, Redmile Group, Mass General Brigham Ventures, Pontifax Venture Capital, RA Capital Management, Samsara BioCapital, New Leaf Venture, Abrdn, BlackRock and other undisclosed investors also participated in the round. The company is a developer of immunomodulatory therapeutics designed for treating both autoimmunity and cancer.
Alzheon: The company raised $126.3 million of Series E venture funding in a deal led by Alerce Medical Technology Partners on February 10, 2025. The company is a developer of a small molecule-based drug discovery platform designed to treat Alzheimer’s disease and other neurodegenerative disorders.
Prenuvo: The company raised $120 million of Series B venture funding in a deal led by Felicis, Left Lane Capital and Forerunner Ventures on February 13, 2025. The company is a developer of a whole-body magnetic resonance imaging scan technology for radiology.
Stellaromics: The company raised $80 million of Series B venture funding in a deal led by Catalyst4 on February 11, 2025, putting the company’s pre-money valuation at $83 million. Stanford University Venture Fund and other undisclosed investors also participated in the round. The company is a developer of gene expression analysis technology that creates fully annotated 3D maps of gene expression within thick tissue samples.
Latent Labs: The company raised $50 million of Series A venture funding in a deal led by Radical Ventures and Sofinnova Partners on February 13, 2025. 8VC, Kindred Capital, Pillar VC, SBXi, Flying Fish Partners, AWS Startups, Jeff Dean, Aidan Gomez, Mati Staniszewski and Isomer Partners also participated in the round. The company applies generative AI technologies to enable biotechnology and pharmaceutical companies to computationally create new molecules for a range of therapeutic, industrial, and environmental uses.
Latigo Bio: The company raised $50 million of venture funding from undisclosed investors on February 13, 2025. The company is an operator of a biotechnology business intended to develop novel and non-opioid therapies for chronic pain.
Allay Therapeutics: The company raised $45 million of Series D venture funding from undisclosed investors on February 10, 2025, putting the company’s pre-money valuation at $69 million. The company is a developer of sustained analgesic products designed to provide post-surgical pain management and recuperation for patients and physicians
Axial Therapeutics: The company raised $19.4 million of venture funding from undisclosed investors on February 11, 2025, putting the company’s pre-money valuation at $30.1 million. The company is a developer of a new class of biotherapeutics designed to treat neurological disorders.
Sensorium Therapeutics: The company raised $14.5 million of venture funding from undisclosed investors on February 12, 2025. The company is a developer of an artificial intelligence product engine designed to discover and develop drugs for central nervous system diseases.
Bioxodes: The company raised EUR 11.2 million of Series A venture funding from undisclosed investors on February 12, 2025. The company is an operator of a clinical-stage biopharmaceutical company intended to treat thrombosis and neuroinflammation in hemorrhagic stroke patients and other indications.
Frontera: The company raised $10 million of venture funding from undisclosed investors on February 14, 2025. The company is a developer of AI-powered tools that help clinicians diagnose and treat children with autism and related disorders more efficiently.
Junevity: The company raised $10 million of venture funding in a deal led by Goldcrest Capital and Godfrey Capital on February 13, 2025. The company is an operator of a rejuvenating medicines company intended to offer therapies for reversing diseases of aging with transcription factor medicines.
TomoWave: The company is in process of raising $10 million of Series A venture funding as of February 15, 2025, putting the company’s pre-money valuation at $15 million. The company is a developer of proprietary quantitative optoacoustic tomography systems designed to aid doctors in detecting cancer and image-guided interventions.
Genomate Health: The company raised $8.4 million of venture funding in the form of SAFE notes from undisclosed investors on February 11, 2025. The company is a developer of a health technology platform designed to provide cancer treatment.
Proficient Health: The company raised $7.1 million of venture funding from undisclosed investors on February 11, 2025. The company is an operator of a healthcare communication platform intended to facilitate communication between physicians, hospitals, and patients in real time.
FLEX Vessel Prep: The company raised $7 million of venture funding in the form of convertible debt from Endeavour Vision and other undisclosed investors on February 12, 2025. The company is a developer of endovascular medical devices intended to address unmet needs in treating peripheral arterial diseases.
Vitalchat: The company raised $6 million of Series A venture funding in a deal led by GHC Industries on February 13, 2025. Other undisclosed investors also participated in the round. The company is a developer of telehealth software designed to connect caregivers, patients, and families using existing workflows on any commodity device.
Hubly Surgical: The company raised $5 million of venture funding from Nextfab Ventures and other undisclosed investors on February 12, 2025. The company is a developer of a medical drill technology for surgical drilling.
BEKHealth: The company raised $4 million of venture funding in a deal led by Boston Millennia Partners and Hatteras Venture Partners on February 14, 2025, putting the company’s pre-money valuation at $19 million. RTI International, WakeMed Hospitals, Excelerate Health Ventures, and Martin Ventures also participated in the round. The company is an AI-powered patient-matching platform for organizations conducting clinical trials and observational studies.
AudioCure: The company raised an undisclosed amount of venture funding in a deal led by Infectopharm Arzneimittel Und Consilium on February 13, 2025. High-Tech Gründerfonds, MED-EL, Hans Rommelspacher and Reimar Schlingensiepen also participated in the round. The company is an operator of a medical research platform intended to offer treatment for incurable hearing loss.
ImmersiveTouch: The company entered into a definitive agreement to receive an undisclosed amount of development capital as of February 10, 2025. The company is a developer of a vendor-neutral enterprise-scale virtual reality surgery platform.
IQ Endoscopes: The company raised an undisclosed amount of venture funding from BGF and Development Bank of Wales on February 10, 2025. The company is a developer of a healthcare technology designed to provide images of the full length of the gut, to help in diagnostics and therapeutic procedures.
Surgical Reality: The company raised an undisclosed amount of venture funding from Lumo Labs and Graduate Entrepreneur on February 13, 2025. The company is a developer of an AI and virtual reality-based medical platform designed for preoperative planning, education, and training.
Ziwig: The company is in the process of raising venture funding from TenNine VC on February 14, 2025. The company is an operator of a diagnostics platform intended to detect the biological modifications responsible for the onset of diseases in patients.
|
